Kako S, Morita S, Sakamaki H, Ogawa H, Fukuda T, Takahashi S, Kanamori H, Onizuka M, Iwato K, Suzuki R, Atsuta Y, Kyo T, Sakura T, Jinnai I, Takeuchi J, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Kanda Y: A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor. Leukemia, 25: 259-265, 2011.
Kobayashi Y, Sakamaki H, Fujisawa S, Ando K, Yamamoto K, Okada M, Ishizawa K, Nagai T, Miyawaki S, Motoji T, Usui N, Iida S, Taniwaki M, Uoshima N, Seriu T, Ohno R: Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. Int J Hematol, 93: 745-749, 2011.
Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Kanamori H, Usuki K, Yamashita T, Watanabe M, Yakushiji K, Yano S, Nawa Y, Taguchi J, Takeuchi J, Tomiyama J, Nakamura Y, Miura I, Kanda Y, Takaue Y, Fukuda T: A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood, 117: 2113-2120, 2011.
Kurosawa S, Yamaguchi T, Uchida N, Miyawaki S, Usuki K, Watanabe M, Yamashita T, Kanamori H, Tomiyama J, Nawa Y, Yano S, Takeuchi J, Yakushiji K, Sano F, Uoshima N, Yano T, Nannya Y, Moriuchi Y, Miura I, Takaue Y, Fukuda T: Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant, 17: 401-411, 2011
Miura K, Takasaki H, Tsujimura H, Kanno M, Maeda Y, Tomita N, Takai K, Masaki Y, Takizawa J, Mori H, Terasaki Y, Yoshida T, Takeuchi J, Motomura S: Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan. Int J Hematol, 93: 684-686, 2011.
Miyashita K, Tomita N, Oshiro H, Matsumoto C, Nakajima Y, Ito S, Matsumoto K, Fujita H, Ishigatsubo Y:Primary hepatic peripheral T-cell lymphoma treated with corticosteroid. Intern Med, 50(6): 617-20, 2011.
Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R: A randomized comparison of four courses of standard-dose multiagent chemotherapy versus three courses of high-dose cytarabine alone in post-remission therapy for acute myeloid leukemia in adults: the JALSG AML201 study. Blood, 117: 2366-2372, 2011.
Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, Miyazaki Y, Ohtake S, Atsuta Y, Sakamaki H, Kawa K, Morishima Y, Ohnishi K, Naoe T, Ohno R: Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia, 25: 41-47, 2011.
Nakagawa Y, Suzuki K, Hirose T, Chou T, Fujisawa S, Kida M, Usuki K, Ishida Y, Taniguchi S, Kouzai Y, Tomoyasu S, Miyazaki K, Higashihara M, Ando K, Aoki S, Arai A, Akiyama N, Hatake K, Okamoto S, Dan K, Ohyashiki K, Urabe A: Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study . J Infect Chemother,17: 58-67, 2011.
Nakaseko C, Ozawa S, Sakaida E, Sakai M, Kanda Y, Oshima K, Kurokawa M, Takahashi S, Ooi J, Shimizu T, Yokota A, Yoshiba F, Fujimaki K, Kanamori H, Sakai R, Saitoh T, Sakura T, Maruta A, Sakamaki H, Okamoto S: Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol, 93:375-382, 2011.
Ono T, Miyawaki S, Kimura F, Kanamori H, Ohtake S, Kitamura K, Fujita H, Sugiura I, Usuki K, Emi N, Tamaki S, Aoyama Y, Kaya H, Naoe T, Tadokoro K, Yamaguchi T, Ohno R, Ohnishi K: for the Japan Adult Leukemia Study Group. BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. Leuk Res, 35: 598-603, 2011.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R.Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: JALSG AML201 Study. Blood, 117: 2358-2365, 2011.
Sakai R, Kanamori H, Nakaseko C, Yoshiba F, Fujimaki K, Sakura T, Fujisawa S, Kawai N, Onoda M, Matsushima T, Maruta A, Sakamaki H, Okamoto S. Air-leak syndrome following allo-SCT in adult patients: report from the Kanto Study Group for Cell Therapy in Japan. Bone Marrow Transplant, 46: 379-384, 2011.
Sakai R, Kanamori H, Motohashi K, Yamamoto W, Matsuura S, Fujita A, Ohshima R, Kuwabara H, Tanaka M, Fujita H, Maruta A, Ishigatsubo Y, Fujisawa S. Long-Term Outcome of Human Herpesvirus-6 Encephalitis after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant, 17: 1389-1394, 2011.
Shigematsu A, Tanaka J, Suzuki R, Atsuta Y, Kawase T, Ito YM, Yamashita T, Fukuda T, Kumano K, Iwato K, Yoshiba F, Kanamori H, Kobayashi N, Fukuhara T, Morishima Y, Imamura M. Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia. Int J Hematol, 94: 463-471, 2011.
Tachibana T, Tanaka M, Numata A, Takasaki H, Ito S, Ohshima R, Hagihara M, Yamazaki E, Tomita N, Fujimaki K, Taguchi J, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H:Pretransplant serum ferritin has a prognostic influence on allogeneic transplantation regardless of disease risk. Leuk Lymphoma, 53(3):456-65, 2011.
Tachibana T, Numata A, Tanaka M, Motohashi K, Fujisawa S, Fujita H, Sakai R, Tomita N, Maruta A, Ishigatsubo Y, Kanamori H:Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion. Leuk Lymphoma, 52(7):1376-9, 2011.
Tachibana T, Tomita N, Furuya M, Yamanaka S, Takeuchi K, Nakamura N, Fujita H, Ishigatsubo Y:Aberrant CD20 expression in angioimmunoblastic T-cell lymphoma. Intern Med, 50(5): 495-9, 2011.
Tachibana T, Tanaka M, Takasaki H, Numata A, Fujisawa S, Maruta A, Harada H, Mori H, Ishigatsubo Y, Kanamori H:Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation. Int J Hematol, 94(6):580-2, 2011.
Tachibana T, Takasaki H, Tanaka M, Maruta A, Hyo R, Ishigatsubo Y, Kanamori H. Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome. Bone Marrow Transplant, 46: 150-151, 2011.
Tachibana T, Tanaka M, Takasaki H, Numata A, Ito S, Watanabe R, Hyo R, Ohshima R, Hagihara M, Sakai R, Fujisawa S, Tomita N, Fujita H, Maruta A, Ishigatsubo Y, Kanamori H. Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies. Int J Hematol, 93: 368-374, 2011.
Tachibana T, Tanaka M, Takasaki H, Numata A, Maruta A, Ishigatsubo Y, Kanamori H. Pre-SCT serum ferritin is a prognostic factor in adult AML, but not ALL. Bone Marrow Transplant. Bone Marrow Transplant, 46: 1268-1269, 2011.
Tachibana T, Numata A, Tanaka M, Motohashi K, Fujisawa S, Fujita H, Sakai R, Tomita N, Maruta A, Ishigatsubo Y, Kanamori H. Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion. Leuk Lymphoma, 52: 1376-1379, 2011.
Tachibana T, Tanaka M, Takasaki H, Numata A, Fujisawa S, Maruta A, Harada H, Mori H, Ishigatsubo Y, Kanamori H. Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation. Int J Hematol, 94: 580-582, 2011.
Tachibana T, Tomita N, Furuya M, Yamanaka S, Takeuchi K, Nakamura N, Fujita H, Ishigatsubo Y. Aberrant CD20 expression in angioimmunoblastic T-cell lymphoma. Intern Med, 50: 495-499, 2011.
Takasaki H, Tachibana T, Tanaka M, Maruta A, Ishigatsubo Y, Kanamori H. A new three-way translocation t(4;11;7)(q21;q23;q22) in a mixed-phenotypea acute leukemia. Case Reports in Hematology. doi:10.1155/2011/148482, 2011.
Tanaka M, Kobayashi S, Numata A, Tachibana T, Takasaki H, Maruta A, Ishigatsubo Y, Kanamori H:The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation. Leuk Res, 36(6):699-703, 2011.
Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujisawa S, Yamauchi T, Uike N, Ando K, Kihara R, Tobinai K, Asou H, Hotta T, Miyawaki S: A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leuk Res, 35: 1384-1389, 2011.
Usui N, Takeshita A, Nakaseko C, Dobashi N, Fujita H, Kiyoi H, Kobayashi Y, Sakura T, Yahagi Y, Shigeno K, Ohwada C, Miyazaki Y, Ohtake S, Miyawaki S, NaoeT, Ohnishi K; for the Japan Adult Leukemia Study Group. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study. Cancer Sci, 102: 1358-1365, 2011.
Waki F, Masuoka K, Fukuda T, Kanda Y, Nakamae M, Yakushijin K, Togami K, Nishiwaki K, Ueda Y, Kawano F, Kasai M, Nagafuji K, Hagihara M, Hatanaka K, Taniwaki M, Maeda Y, Shirafuji N, Mori T, Utsunomiya A, Eto T, Nakagawa H, Murata M, Uchida T, Iida H, Yakushiji K, Yamashita T, Wake A, Takahashi S, Takaue Y, Taniguchi S. Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. Biol Blood Marrow Transplant, 17: 841-851, 2011.
Yoshida M, Akiyama N, Fujita H, Miura K, Miyatake J, Handa H, Kito K, Takahashi M, Shigeno K, Kanda Y, Hatsumi N, Ohtake S, Sakamaki H, Ohnishi K, Miyawaki S, Ohno R, Naoe T. Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol, 93: 66-73, 2011.
Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol, 29: 4410-4416, 2011.
